Non Small Cell Lung Cancer - pembrolizumab - RAD51B promoter methylation + PD-L1 expression

Association details:

Biomarker:	RAD51B promoter methylation + PD-L1 expression
Cancer:	Non Small Cell Lung Cancer
Drug:	Keytruda (pembrolizumab) (PD1 inhibitor)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C3 – Early Trials

Source:

J Clin Med

Title:

RAD51Bme Levels as a Potential Predictive Biomarker for PD-1 Blockade Response in Non-Small Cell Lung Cancer

Published date:

04/08/2020

Excerpt:

Remarkably, combining RAD51Bme+ with PD-L1+ improved the sensitivity of the test (68%) to predict immunotherapy response, maintaining high specificity (85%) and increasing positive predictive value (94%)….PD-L1+ and RAD51Bme+ are promising biomarkers to predict response to PD-1 blockade rather than overall prognostic factors in NSCLC’s patients.